Burkitt lymphoma (BL) can be morphologically indistinguishable from diffuse large B-cell lymphoma (DLBCL).The 2008 WHO classification includes a subcategory of aggressive lymphomas characterized by features intermediate between DLBCL and BL in order to accommodate cases in the gray zone between BL and DLBCL. Rearrangement of the MYC gene is found in 3% to 16% of DLBCLs and in nearly 100% of BL.Identifying MYC status is important in establishing final diagnosis of DLBCL, BL, or B-cell lymphoma, with features intermediate between DLBCL and BL as well as in differential diagnoses of the lymphomas. Results from one study have shown immunohistochemical (IHC) expression of MYC protein by c-Myc antibody in 219 cases of aggressive DLBCL and 7 cases of BL.Nuclear MYC protein expression detected by IHC has shown high sensitivity and specificity in identifying a MYC rearrangement in aggressive DLBCL and BL when at least 70% of lymphoma cells show nuclear positivity.
The IHC c-Myc assay, combined with other antibodies, such as those against CD10, BCL2, and Ki67, is very useful in identifying cases for which MYC FISH analysis is warranted or can be omitted.There are reports that nuclear overexpression of MYC protein occur frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. However, MYC protein overexpression has yet to be correlated with gain of MYC gene (8q24), suggesting alternative mechanisms for MYC protein overexpression.
c-Myc Positive Control Slides, Product No. 395S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.
Download the latest released IFU
Note: This IFU may not apply to your specific product lot.
For Technical Service please contact: 800-665-7284 or email: email@example.com
Cell Marque is a trademark of sigma-aldrich Co. LLC
|antibody product type
|For In Vitro Diagnostic Use in Select Regions (See Chart)
|buffered aqueous solution
|vial of 0.1 mL concentrate (395R-14)
vial of 0.5 mL concentrate (395R-15)
bottle of 1.0 mL predilute (395R-17)
vial of 1.0 mL concentrate (395R-16)
bottle of 7.0 mL predilute (395R-18)
|immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
|Burkitt lymphoma, prostate carcinoma